These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32735150)

  • 41. Association between selected gene polymorphisms and statin metabolism, risk of ischemic stroke and cardiovascular disorders.
    Kotlęga D; Gołąb-Janowska M; Masztalewicz M; Ciećwież S; Nowacki P
    Postepy Hig Med Dosw (Online); 2016 May; 70():435-47. PubMed ID: 27180962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers.
    Zhao G; Liu M; Wu X; Li G; Qiu F; Gu J; Zhao L
    Pharmacogenomics; 2017 Jan; 18(1):65-75. PubMed ID: 27967318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report.
    Kiage J; Venkatanarayan A; Roth M; Elam M
    J Clin Lipidol; 2022; 16(1):23-27. PubMed ID: 34887219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens.
    Lusiki Z; Blom D; Soko ND; Malema S; Jones E; Rayner B; Blackburn J; Sinxadi P; Dandara MT; Dandara C
    OMICS; 2024 Jun; 28(6):261-279. PubMed ID: 37956269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenetics of response to statins.
    Zineh I
    Curr Atheroscler Rep; 2007 Sep; 9(3):187-94. PubMed ID: 18241612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SNP of HMGCR and Apo E genes and their impact in response to statin therapy in hypercholesterolemic and hypertriglyceridemic patients in Pakistan.
    Rizwan M; Aslam N; Ashfaq UA; Hayat M; Hussain SM
    Pak J Pharm Sci; 2021 Jul; 34(4(Supplementary)):1577-1583. PubMed ID: 34799335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
    Gupta A; Harris JJ; Lin J; Bulgarelli JP; Birmingham BK; Grimm SW
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5986-94. PubMed ID: 27458210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seventeen years of statin pharmacogenetics: a systematic review.
    Leusink M; Onland-Moret NC; de Bakker PI; de Boer A; Maitland-van der Zee AH
    Pharmacogenomics; 2016; 17(2):163-80. PubMed ID: 26670324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.
    Ranasinghe P; Sirisena N; Ariadurai JN; Vishnukanthan T; Thilakarathne S; Anandagoda G; Dissanayake VH
    Pharmacogenomics; 2023 Oct; 24(15):809-819. PubMed ID: 37877238
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin regulation of CYP3A4 and CYP3A5 expression.
    Willrich MA; Hirata MH; Hirata RD
    Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity.
    Jawaid S; Gertz M; Corsino C; Cheung J; Seidle H; Couch RD
    Indian J Biochem Biophys; 2010 Dec; 47(6):331-9. PubMed ID: 21355415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events.
    Hubacek JA; Vrablik M
    Drug Metabol Drug Interact; 2011; 26(1):13-20. PubMed ID: 21557673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis.
    Wojtyniak JG; Selzer D; Schwab M; Lehr T
    Clin Pharmacol Ther; 2021 Jan; 109(1):201-211. PubMed ID: 33280091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.
    Murphy C; Deplazes E; Cranfield CG; Garcia A
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
    Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
    Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The frequency of rs2231142 in
    AlAzzeh O; Roman YM
    Pharmacogenomics; 2023 Feb; 24(3):173-182. PubMed ID: 36661065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.